)
Conclusions:
This case series provides encouraging initial evidence that
methylone may have utility in the pharmacological treatment of
PTSD.
Methylone produced rapid symptom improvement, as
measured by CGI-I ,in highly complex patients with
significant disease (baseline CGI-S scores: 4 to 7).
The majority (81%) of patients achieved scores per CGI-I
corresponding to “much improved” or “very much
improved.”
Methylone was well-tolerated over a broad dose range
(100 to 1,020 mg) with both single and multiple
administrations.
Adverse events were reported only in three older patients,
age ≥70; these were mild and required no intervention.
Notably, none of these adverse events occurred in patients receiving
concomitant SSRI therapy, which is noteworthy as MDMA trials
have required patients to taper off these medications.
